Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift
Injection pens for the weight loss treatment Wegovy, manufactured by Novo Nordisk A/S, on display during a news conference in Mumbai, India, June 24, 2025. Dhiraj Singh | Bloomberg | Getty Images Millions of older Americans in Medicare are about to gain access to obesity drugs for the first time — but that landmark shift